



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/58473</b> <b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)																											
<b>(21) International Application Number:</b> PCT/US00/08621 <b>(22) International Filing Date:</b> 31 March 2000 (31.03.00)  <b>(30) Priority Data:</b> <table border="0"> <tr> <td>60/127,607</td> <td>31 March 1999 (31.03.99)</td> <td>US</td> </tr> <tr> <td>60/127,636</td> <td>2 April 1999 (02.04.99)</td> <td>US</td> </tr> <tr> <td>60/127,728</td> <td>5 April 1999 (05.04.99)</td> <td>US</td> </tr> <tr> <td>09/540,763</td> <td>30 March 2000 (30.03.00)</td> <td>US</td> </tr> </table> <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</b> <table border="0"> <tr> <td>US</td> <td>60/127,607 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>31 March 1999 (31.03.99)</td> </tr> <tr> <td>US</td> <td>60/127,636 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 April 1999 (02.04.99)</td> </tr> <tr> <td>US</td> <td>60/127,728 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>5 April 1999 (05.04.99)</td> </tr> <tr> <td>US</td> <td>09/540,763 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>30 March 2000 (30.03.00)</td> </tr> </table> <b>(71) Applicant (for all designated States except US):</b> CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).	60/127,607	31 March 1999 (31.03.99)	US	60/127,636	2 April 1999 (02.04.99)	US	60/127,728	5 April 1999 (05.04.99)	US	09/540,763	30 March 2000 (30.03.00)	US	US	60/127,607 (CIP)	Filed on	31 March 1999 (31.03.99)	US	60/127,636 (CIP)	Filed on	2 April 1999 (02.04.99)	US	60/127,728 (CIP)	Filed on	5 April 1999 (05.04.99)	US	09/540,763 (CIP)	Filed on	30 March 2000 (30.03.00)	<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US).  <b>(74) Agent:</b> ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
60/127,607	31 March 1999 (31.03.99)	US																											
60/127,636	2 April 1999 (02.04.99)	US																											
60/127,728	5 April 1999 (05.04.99)	US																											
09/540,763	30 March 2000 (30.03.00)	US																											
US	60/127,607 (CIP)																												
Filed on	31 March 1999 (31.03.99)																												
US	60/127,636 (CIP)																												
Filed on	2 April 1999 (02.04.99)																												
US	60/127,728 (CIP)																												
Filed on	5 April 1999 (05.04.99)																												
US	09/540,763 (CIP)																												
Filed on	30 March 2000 (30.03.00)																												
<b>(54) Title:</b> NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"  <b>(57) Abstract</b> <p>The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.</p>																													

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is any integer 1-3161, or the complement thereof.
2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is any integer 1-3161, or the complement thereof.
3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 $n$ , wherein  $n$  is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SI ID NO: 2 $n$ .
4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 $n$ , wherein  $n$  is any integer 1-3161.
5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprise the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is any integer 1-3161, or the complement thereof.
6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is a integer 1-3161, or the complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.

8. The vector of claim 7, wherein said vector is an expression vector.
9. A host cell comprising the isolated nucleic acid molecule of claim 1.
10. A substantially purified polypeptide comprising an amino acid sequence at least 80% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:  $2n$ , wherein  $n$  is any integer 1-3161.
11. The polypeptide of claim 10, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:  $2n$ , wherein  $n$  is any integer 1-3161.
12. An antibody that selectively binds to the polypeptide of claim 10.
13. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of:
  - a) the nucleic acid of claim 1;
  - b) the polypeptide of claim 10; and
  - c) the antibody of claim 12;and a pharmaceutically acceptable carrier.
14. A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 13.
15. A method of producing the polypeptide of claim 10, said method comprising culturing the host cell of claim 9 under conditions in which the nucleic acid molecule is expressed.
16. A method of detecting the presence of the polypeptide of claim 10 in a sample, comprising contacting the sample with a compound that selectively binds to said polypeptide under conditions allowing the formation of a complex between said polypeptide and said

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample. .

18. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected from the group consisting of:

- a) the nucleic acid of claim 1;
- b) the polypeptide of claim 10; and
- c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

- b) measuring expression the activity of said protein in said test subject;
- c) measuring the activity of said protein in a control subject that recombinantly expresses said protein and is not at increased risk for an ORFX-associated disorder; and
- d) comparing expression of said protein in said test subject and said control subject, wherein a change in the activity of said protein in said test subject relative to said control subject indicates the test compound is a modulator or of latency of predisposition to an ORFX-associated disorder.

22. The method of claim 20, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

23. A method for determining the presence of or predisposition to a disease associated with altered levels of a polypeptide of claim 11 in a subject, the method comprising:

- a) measuring the amount of the polypeptide in a sample from said subject; and
- b) comparing the amount of said polypeptide in step (a) to the amount of the polypeptide present in a control sample,

wherein an alteration in the level of the polypeptide in step (a) as compared to the control sample indicates the presence of or predisposition to a disease in said subject.

24. The method of claim 23, wherein said subject is a human.

25. A method for determining the presence of or predisposition to a disease associated with altered levels the nucleic acid molecule of claim 1 in a subject, the method comprising:

- a) measuring the amount of the nucleic acid in a sample from the mammalian subject; and
- b) comparing the amount of said nucleic acid in step (a) to the amount of the nucleic acid present in a control sample,

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.

```

      1           5           10           15
Ser Thr Ser Gly Ile Ile Ser Cys Phe Ser Gln Val Ser Lys Ser Ser
      20           25           30
Ala Pro Phe Ser Ser Thr Ser Phe Ser Val Pro Lys Lys Ala Arg Ala
      35           40           45
Asp Cys Thr Cys Ile Ser Thr Ala Glu Leu Phe Ile Cys Asp Ser Ala
      50           55           60
Phe Phe Arg Ser Ser Gly Ser Arg Glu Arg His Ser Phe Lys Val Phe
      65           70           75           80
Phe Leu Cys Ile Pro Pro Pro Leu His Ala
      85           90

```

&lt;210&gt; 2629

&lt;211&gt; 650

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2629

```

acgcgtgaag ggtctacagg cagtgaagtga aggccaggag cagggcccag gccaggcacg
60
accaccgagg ggatgaactt cacagtgggt ttcaagccgc tgctagggga tgcacacagc
120
atggacaacc tggagaagca gtcctctgctg cccatctgccc tggagatgtt ctccaaacca
180
gtgggtgatcc tgccctgccca acacaacctg tgccgcaaat gtgccaacga cgtcttccag
240
gtgggtgccca gggacgggca gggccaggta aagcaatgca gacctgtggg ggactgatca
300
ggtcagagct gagaccccag aaggatgatgg atagagtgtc ctctgagggtg ggtgggtggct
360
gttgtggctg gagagcagaa gggctggggt ccaagcaaat cccagagcaa gcatgagtcn
420
agcagctgcc ctgcaggctg gcaggtagag cctgtgcata gacggcagct ggagtgtctg
480
gatctaccaa ggaaagtaga ccctgtggaa actgggagggg aggggtatccc acaccgggct
540
ttataagagc ctgtgccaga ctctgcattc cagtttgag tttcagactt cgagagcatt
600
gtggaaaata cggagaaaag attaatgaga taatgaaacg ttaaaaaaaaa
650

```

&lt;210&gt; 2630

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2630

```

Met Asp Asn Leu Glu Lys Gln Leu Ile Cys Pro Ile Cys Leu Glu Met
      1           5           10           15
Phe Ser Lys Pro Val Val Ile Leu Pro Cys Gln His Asn Leu Cys Arg
      20           25           30
Lys Cys Ala Asn Asp Val Phe Gln Val Gly Ala Arg Asp Gly Gln Gly
      35           40           45
Gln Val Lys Gln Cys Arg Pro Val Gly Asp

```

50

55

<210> 2631  
<211> 5124  
<212> DNA  
<213> Homo sapiens

<400> 2631  
caagatattg aaaggcta atcatcagagt gatatcatag atcgtgtggt atatgacttg  
60  
gataacccaa attacacccat tccagaagag ggagatattt tgaaatttaa ctccaaattt  
120  
gagtctggga atctgcgcaa agtaattcaa attagaaaaa atgaatatga tcttattctg  
180  
aactcagaca taaacagcaa tcattatcat cagtggtttt actttgaagt cagtggaaatg  
240  
cgaccagggtg ttgcttacag gtttaacatc attaactgtg aaaagtccaa cagtcagttt  
300  
aattatggta tgcaaccact catgtattcg gttcaggaag cattaatatgc cagaccatgg  
360  
tggattcgta tggggactga catttggtac tataaaaatc atttctcaag aagttcagtt  
420  
gctgcagggtg ggcaaaaggg aaaatcctac tatacaatta catttactgt caattttcca  
480  
cataaagatg atgtttgcta ctttgcctat cactatccat atacgtattc aactttacag  
540  
atgcatcttc aaaaattgga atcagcacac aatcctcagc aaatctattt tcggaaagat  
600  
gtgttatgtg aaaccctgtc tggaaacagc tgccccttgg tgactataac agcaatgcc  
660  
gagtctaatt attatgaaca tatctgcat ttcagaaatc gcccttacgt tttctgtct  
720  
gctcgggtac atcctggaga aactaatgca agttgggtta tgaaaggaac gttggaatat  
780  
ctcatgagca ataacccac tgcacagagc ttactagaat cttatatttt taaaattgtc  
840  
cctatgttaa atccagatgg tgcacatcat ggaaatcatc gctgttcttt aagtggagag  
900  
gatttgaata ggcagtggca aagtccaagt ccgattttac atcctacaat ttaccatgct  
960  
aaggggctgt tgcaatactt ggctgcagtg aagcgtttac ccttggttta ttgtgattat  
1020  
catggccatt cccgaaagaa gaatgtattt atgtatgggt gcagcatcaa agagacagt  
1080  
tggcatacca atgataatgc aacttcattg gatgtgtgtg aggatacggg atacaggaca  
1140  
ttgcctaaga tactgagcca tctgcccc gcatcttgca tgagcagctg tagcttcgta  
1200  
gtggaaaaat ctaaagaatc cacagcacgt gttgtagttt ggagggaaat aggagtacaa  
1260  
agaagttata ccatggagag tactttatgt ggctgtgatc agggaaaata caagggttta  
1320  
cagattggta cccgagaact ggaagagatg ggagcaaat tttgtgttgg tcttttacgt  
1380